Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder / Marcio Versiani en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 28-34 Título : Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder Tipo de documento: texto impreso Autores: Marcio Versiani, Autor ; Mohammed Amin, Autor ; Guy Chouinard, Autor Fecha de publicación: 2023 Artículo en la página: pp. 28-34 Idioma : Inglés (eng) Idioma original : Inglés (eng) Etiquetas: Antidepresivos, Trastorno depresivo mayor, Morfolinas. Resumen: The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis. Link: ./index.php?lvl=notice_display&id=31228 [artículo] Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder [texto impreso] / Marcio Versiani, Autor ; Mohammed Amin, Autor ; Guy Chouinard, Autor . - 2023 . - pp. 28-34. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 28-34 Etiquetas: Antidepresivos, Trastorno depresivo mayor, Morfolinas. Resumen: The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis. Link: ./index.php?lvl=notice_display&id=31228

Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group / Guy Chouinard en The Canadian Journal of Psychiatry, Año 1998 Vol. 43 - No. 10 (Diciembre)

Público ISBD [artículo]  inThe Canadian Journal of Psychiatry > Año 1998 Vol. 43 - No. 10 (Diciembre) . - pp. 1018–1025 Título : Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group Tipo de documento: texto impreso Autores: Guy Chouinard, Autor Fecha de publicación: 2022 Artículo en la página: pp. 1018–1025 Idioma : Inglés (eng) Idioma original : Inglés (eng) Etiquetas: Antipsicóticos, Enfermedad crónica, Examen neurológico, Risperidona, Esquizofrenia, Psicología esquizofrénica Resumen: Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia. Link: ./index.php?lvl=notice_display&id=29170 [artículo] Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group [texto impreso] / Guy Chouinard, Autor . - 2022 . - pp. 1018–1025. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Canadian Journal of Psychiatry > Año 1998 Vol. 43 - No. 10 (Diciembre) . - pp. 1018–1025 Etiquetas: Antipsicóticos, Enfermedad crónica, Examen neurológico, Risperidona, Esquizofrenia, Psicología esquizofrénica Resumen: Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia. Link: ./index.php?lvl=notice_display&id=29170

Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder / Howard C. Margolese en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 347-352 Título : Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder Tipo de documento: texto impreso Autores: Howard C. Margolese, Autor ; Guy Chouinard, Autor ; Linda Beauclair, Autor Fecha de publicación: 2023 Artículo en la página: pp. 347-352 Idioma : Inglés (eng) Idioma original : Inglés (eng) Etiquetas: Antipsicóticos, Tolerancia al medicamento, Psicosis inducidas por sustancias, Trastornos psicóticos, Esquizofrenia. Resumen: A 3-year open-label study was conducted to determine the long-term safety and efficacy of quetiapine monotherapy in schizophrenia and schizoaffective disorder. Twenty-three male outpatients previously stable but with inter-episode residual symptoms on classical antipsychotics and/or risperidone and who had complained of side effects were selected. Link: ./index.php?lvl=notice_display&id=31049 [artículo] Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder [texto impreso] / Howard C. Margolese, Autor ; Guy Chouinard, Autor ; Linda Beauclair, Autor . - 2023 . - pp. 347-352. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 347-352 Etiquetas: Antipsicóticos, Tolerancia al medicamento, Psicosis inducidas por sustancias, Trastornos psicóticos, Esquizofrenia. Resumen: A 3-year open-label study was conducted to determine the long-term safety and efficacy of quetiapine monotherapy in schizophrenia and schizoaffective disorder. Twenty-three male outpatients previously stable but with inter-episode residual symptoms on classical antipsychotics and/or risperidone and who had complained of side effects were selected. Link: ./index.php?lvl=notice_display&id=31049

---

1 (1 - 3 / 3) Por página: 25 50 100 200